UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): September 11, 2017

 

Legacy Ventures International, Inc.
(Exact name of registrant as specified in its charter)

 

Nevada   333-199040   30-0826318

(State or other jurisdiction

of incorporation)

  (Commission File Number)  

(IRS Employer

Identification No.)

 

1382 Valencia Ave., Suite F

Tustin, CA 92780

(Address of Principal Executive Offices)

 

(949) 260-8070

Registrant’s telephone number, including area code
  

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company      ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    

 

 

 

 

 

 

Item 1.01 Entry into a Material Definitive Agreement.

 

Share Exchange Agreement and Subscriptions

 

Effective September 11, 2017 (the “Closing Date”), Legacy Ventures International, Inc., (the “Company”) entered into that certain Share Exchange Agreement (the “Share Exchange Agreement”), dated as of September 1, 2017, by and among the Company, Nexalin Technology, Inc., a Nevada corporation (“Nexalin”) and shareholders of Nexalin holding a majority of the issued and outstanding shares of Nexalin common stock (the “Nexalin Shareholders”). Pursuant to the Share Exchange Agreement, the Company agreed to exchange the outstanding equity stock of Nexalin held by the Nexalin Shareholders for units (the “Units”) consisting of an aggregate of approximately 25,000,000 newly issued shares of the Common Stock, $0.001 par value, of the Company and warrants (the “Warrants”) to purchase an aggregate of approximately 25,000,000 newly issued shares of the Common Stock, $0.001 par value, of the Company. The warrants are two-year warrants exercisable at the end of one year for exercise prices between $1.50 and $1.75 per share, payable in cash. The warrants are must be promptly exercised, and subject to forfeiture if not so exercised, if the Company’s shares achieve a trading price of $3.00 or more for 30 consecutive days. At the Closing Date, the Company approved the issuance of approximately 15,500,000 shares of common stock to the Nexalin shareholders, together with warrants for the purchase of an additional 15,500,000 shares and reserved approximately 9,500,000 additional shares, together with the related warrants, for the issuance to remaining Nexalin shareholders who are expected to execute and deliver the Share Exchange Agreement, including approximately 1,100,000 shares and related warrants issuable immediately to consultants in connection with the transactions contemplated by the Share Exchange Agreement. As of the date of the filing of this Current Report on Form 8-K, the holders of a majority of the equity securities of Nexalin have exchanged their shares into a majority of the shares of the issued and outstanding shares of the Company’s common stock.

 

As a result of the Share Exchange Agreement and the other transactions contemplated thereunder, Nexalin is now a majority subsidiary of the Company.

 

All descriptions of the Share Exchange Agreement and Warrants herein are qualified in their entirety by reference to the text thereof filed as Exhibits 2.1 and 2.2 hereto, which is incorporated herein by reference. The Share Exchange Agreement governs the contractual rights between the parties in relation to the transactions contemplated thereby and contains customary representations and warranties and pre- and post-closing covenants of each party. The Share Exchange Agreement is not intended to be, and should not be relied upon as, making disclosures regarding any facts and circumstances relating to the Company or Nexalin. The Share Exchange Agreement is described in this Current Report on Form 8-K and attached as Exhibits 2.1 and 2.2 hereto only to provide investors with information regarding the terms and conditions of the Share Exchange Agreement, and, except for its status as a contractual document that establishes and governs the legal relationship among the parties thereto with respect to the transactions contemplated thereby, is not intended to provide any other factual information regarding the Company or Nexalin or the actual conduct of their respective businesses during the pendency of the Share Exchange Agreement, or to modify or supplement any factual disclosures about the Company contained in any of the Company’s public reports filed with the Securities Exchange Commission (the “SEC”). The representations and warranties contained in the Share Exchange Agreement have been negotiated with the principal purpose of establishing the circumstances under which a party may have the right not to consummate the transaction if the representations and warranties of the other party prove to be untrue due to a change in circumstance or otherwise, and of allocating risk between the parties, rather than establishing matters as facts. These representations, warranties and covenants were made as of specific dates and only for purposes of the Share Exchange Agreement, not for the benefit of any investors, and are subject to important exceptions and limitations, including a contractual standard of materiality different from that generally relevant to investors, and are qualified by information in confidential disclosure schedules that the parties exchanged in connection with the execution of the Share Exchange Agreement. The parties reserve the right to, but are not obligated to amend or revise the Share Exchange Agreement. Accordingly, investors should not rely on representations and warranties as characterizations of the actual state of facts, or for any other purpose, at the time they were made or otherwise.

 

This current report on Form 8-K is issued in accordance with Rule 135c under the Securities Act, and is neither an offer to sell any securities, nor a solicitation of an offer to buy, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

 

  2  

 

 

Convertible Promissory Note

 

On September 11, 2017, the Company issued a Convertible Promissory Note to an accredited investor. The Note has an aggregate principal amount of $500,000 and matures one year from the date of issuance (the “Maturity Date”) and has an interest rate of 8% per annum. The holder may convert the Notes at any time up to the Maturity Date into shares of the Company’s common stock, par value $0.001 per share, at a conversion price equal to $1.00 per share and the note will automatically convert upon the filing of the audited financial statement for Nexalin by the Company.

 

Item 2.01 Completion of Acquisition or Disposition of Assets.

 

The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference.

 

As described in Item 1.01 above, effective September 1, 2016, the Company entered into a Share Exchange Agreement which resulted in Nexalin becoming our majority-owned subsidiary.

 

Nexalin, a Nevada corporation, was formed in October 2010. The Company is an information technology company which provides a safe, non-invasive and drug free treatment that is cleared by the FDA for the treatment of anxiety, depression and insomnia. The Nexalin device emits a patented, frequency-based waveform that interacts with structures of the mid-brain that help to regulate and stabilize neurochemicals.

 

Nexalin products/treatments (“Nexalin Therapy”) is classified at the FDA as “Cranial Electrical Stimulation”. Nexalin Therapy is a class III medical device and is FDA cleared and indicated for the treatment of depression, anxiety and insomnia. These are also the symptoms associated with more complex issues such as PTSD, substance abuse and other addictive behaivors. Nexalin has also received the CE European clearance for the treatment of chronic pain in addition to Anxiety, Depression and Insomnia.

 

Unfortunately most mental health treatment models are based on the symptomatic treatment associated with pharmaceutical medication. Recently new evidenced based articles have published statements that many of these medications have an actual effective rate of less than 30%. Additionally, there are many unpleasant side effects and addictive qualities associated with medications. The future of mental health treatment is based on stimulating areas of the brain that may be responsible for the underlying cause of these disorders. With the advancement of neuro-imaging techniques in the last 10 years, new evidence has indicated that many of the underlying causes of mental health challenges can be identified in the mid-brain. This is the area that Nexalin has focused their advanced stimulation technology.

 

Nexalin Therapy utilizes a new patented waveform that is highly effective in stimulating the Hypothalamus and other structures in the mid-brain associated with mental health issues. Data suggests the Nexalin Therapy waveform effectively resets these structures of the brain without the introduction of pharmaceutical medication. A major function of the hypothalamus is to maintain homeostasis in the brain by constantly sensing and adapting to information received by the brain. When an individual is faced with a traumatic life event, the hypothalamus appears unable to maintain normal levels of Serotonin, Dopamine, Beta-endorphins and other Neurotransmitters. The result of reduced levels of these important neurochemicals can be anxiety, depression, and insomnia and other related mental health issues. All of which can increase in frequency and severity if not treated. The Nexalin Therapy treatment stimulates the brain with an undetectable electrical frequency that is transmitted via a proprietary waveform. The waveform affects key brain structures that are involved in the regulation of its neurotransmitters.

 

Nexalin Therapy has an effective rate of over 70% in patients in company testing and research. Patients report an average reduction of 81% to 85% for their primary and secondary symptoms. Clinical results and early research indicates that 10-15 treatments will begin stabilizing the brain by normalizing the levels of various neurotransmitters by increasing the production of Beta-endorphins. Early research indicates base line beta-endorphin concentration of the Cerebral Spinal Fluid (CSF) was 1.5 times lower than that of normal healthy subjects. After 40 minutes of the Nexalin Therapy stimulation, the average CSF beta-endorphin concentrations increased 380%. Additional research indicates the effects are long lasting and addresses the underlying causes of the associated symptoms. Nexalin Therapy consists of 10 - 15 consecutive daily treatment sessions which last 40 minutes. Nexalin Therapy is administered non-invasively to the patient via three electrodes, one placed on the forehead and one placed behind each ear located on the mastoid area of the temporal bone. The therapy itself delivers a mild, unique frequency based waveform that is administered through the electrodes into the mid brain. Through this repetitive stimulation of the hypothalamus, Nexalin Therapy can trigger significant changes in the levels of important neurochemicals within the brain. We believe that Nexalin Therapy assists the hypothalamus to re-establish and sustain normal levels of neurochemicals in the brain.

 

  3  

 

 

Nexalin Therapy is currently being used in several settings around the country. We believe that Nexalin Therapy provides benefit for patients that are not responding to traditional pharmaceutical intervention or want to decrease dosage over time and reduce side effects. We believe that Nexalin Therapy is also demonstrating tremendous opportunity in the addiction community by reducing the symptoms associated with addiction such as anxiety and depression. By addressing these symptoms, Nexalin Therapy is also decreasing the cravings issue associated with chronic relapse. Relapse conditions and mid-brain functional issues associated with active addictions are mitigated by the normalization of the brain’s neurochemistry.

 

Nexalin’s Management Team consists of:

 

Randall Letcavage – Chief Executive Officer, President, Chief Financial Officer and Chairman of the Board of Directors

 

Mr. Letcavage was named Chairman, President, Chief Executive Officer, and Chief Financial Officer of the Company on June 28, 2017. Mr. Letcavage has been the Chief Executive Officer of Nexalin since inception in 2010. Mr. Letcavage is also Chairman, President, Chief Executive Officer, and Chief Financial Officer of Premier Holding Corporation, since July 5, 2012. Prior to this he was employed as a consultant by Capital Finance LLC. He brings in excess of 25 years plus of business experience specializing in the financial markets and business consulting including biotech, green energy/clean technology. For the past 20 years Mr. Letcavage has been an investment banker widely recognized for individual achievements as well as his role of Founder, Officer and Director of the iCapital Group that includes iCapital Finance Inc, iCapital Advisory LLC and iCap Development LLC (A National “CDE” Community Development Entity – Certified by the U.S Treasury Department). Mr. Letcavage has also held executive positions, invested, and/or operated numerous businesses including related companies in life sciences, medical devices and green energy and power reduction – CEO of Ciralight Global Inc, CEO of Green Central Holdings, Consultant and one of the largest shareholders of publicly traded PRHL which operates The Power Company, American Illuminating and Energy Efficiency Experts (E3). Letcavage had been successful in many areas additionally providing capital to healthcare companies. Mr. Letcavage personally acted as an advisor to municipalities, including the Stare of New Jersey and its Economic Development Authority, and leading millions in industrial bond transactions, as well as New Market Tax Credits, while also advising the National Conference of Black Mayors (NCBM; over 800 members in these matters). Mr. Letcavage served as the Managing Director of NC Capital Markets and as Vice President of The National Capital Companies, Inc. (directing the daily operations of most of its subsidiaries). Mr. Letcavage was formerly the CEO and a majority owner of Capital Access Group. Prior to Capital Access, Mr. Letcavage founded and/or managed several asset management firms, including Valley Forge Capital Holdings and the Marshall Plan, LLC that directed and/or co-managed over $3 billion in assets with former renowned CALPERS (California Pension & Retirement Systems) Manager, Greta Marshall. Prior to Valley Forge, Mr. Letcavage founded Security America, Inc., an asset management firm based in Grosse Pointe, Michigan. Mr. Letcavage worked with Prudential-Bache running a Joint Venture ―High Net Worth Group (a/k/a Security American, Inc.).

 

Mark White

Chief Operating Officer

 

Mark has been a successful entrepreneur for 20 years; he specializes in the performance of service based companies. He has extensive experience in growth organizations and turnaround situations. He has had numerous successes building teams and implementing effective processes, with an emphasis on organizational development, financial stability and the quality and efficiency of services.

 

Mr. White has spent the last six years studying the Nexalin Technology in the patient and practitioner community. In 2010, Mr. White’s distribution company, iiCOM Strategic, became the first national distribution provider for Nexalin. His recent development of clinical models utilizing the Nexalin Therapy has positioned him as a provider of consulting aspects related to the use of Nexalin in clinical applications across the United States.

 

  4  

 

 

In January of 2012, Mr. White joined the Nexalin corporate team to oversee operations and the development of a successful clinical model. Mr. White is an experienced and well-respected trainer and presenter internationally on the subject of “Brain Based Health” and “Brain Based Recovery”. He is a thought leader in the application of brain stimulation and its ability to address mental health and addiction issues in the United States. Mr. White has also appeared on several prominent news and media shows speaking on Nexalin and electrical brain stimulation as a form of drug free treatment for various psychiatric disorders.

 

In addition to his considerable responsibilities with Nexalin, Mr. White is the Founder and Director of Unique Mind Care in Houston, TX, a clinical leader in the in the brain health arena focused on drug free treatments that utilize QEEG training technologies and various neurostimulation techniques.

 

Medical Advisory Board

 

Nexalin also utilizes a Medical Advisory Board, consisting of the following medical professionals:

 

Dr. Mark G. Agresti, M.D. P.A.

 

Dr. Agresti was raised in New Jersey and came to Florida after completing medical training. He attended Tulane University in New Orleans, LA for premed. The Chicago Medical School for medical school, and completed his Residency in Psychiatry at Roosevelt Hospital in New York City. He is Board Certified in the Practice of Psychiatry.

 

He has been in private practice in West Palm Beach, FL for 20 years and has been on the staff of Columbia Hospital and several Addiction Treatment centers. He served as Chairman of the Department of Psychiatry at Columbia Hospital and medical director for the various treatment centers.

 

Dr Agresti’s practice focuses on the treatment of mental illness addictions and dual diagnosis. He has expanded his addictions practice to include outpatient detoxification from both drugs and alcohol. His patient population includes both children and adults.

 

Suzie Schuder, MD

 

Dr. Schuder is Board Certified by the American Board of Psychiatry and Neurology. She is a founding member and vice president of the World Society of Antiaging Medicine (WOSAAM), a founding member of the International Hormone Society, and a member of the International Society of Psychoneuroendocrinology (ISPNE), and the American Society of Addiction Medicine and a Diplomate of the American Board of Anti-Aging Medicine.

 

Dr. Schuder has made it her mission to educate doctors about her common-sense methods in providing a holistic, pro-health approach to patient care, particularly in psychiatry . She also devotes time to lecturing physicians at a variety of international venues on topics related to the mind and emotions and the major life altering impact of hormones, nutrients and toxins. Dr. Schuder also takes the time to teach medical students who rotate through her unique psychiatric practice.

 

Dr. Schuder provides total patient care through a balanced treatment approach by merging the best of traditional medicine with science-based alternative solutions to provide excellence in patient care. She recently added a Nexalin, a unique transcranial electrostimulation device that provides significant, enduring improvements in patients with depression, anxiety and insomnia.

 

Irene Cergnul, MD

 

Dr. Irene Cergnul completed her post-graduate training at Bronx Lebanon Hospital Center in New York and after her final year as Chief Resident was recruited as Assistant Professor in the Department of Family Medicine. She worked as the Medical Director in the in-patient service and also taught residents in training for the next four years. She was a Research Coordinator involving multiple studies on HIV, depression, as well as neuropathy, and is a co-author on several publications.

 

  5  

 

 

Dr. Cergnul then transitioned to Montefiore Medical Center at the Substance Abuse Treatment Program where she provided direct medical care to patients, as the Director of HIV Services, and also held Assistant Professorship positions in both the Departments of Family Medicine and Psychiatry. She taught Family Medicine residents, Psychiatry residents and fellows in Addiction Psychiatry.

 

Dr. Cergnul is Board Certified in Family medicine as well as Addiction Medicine and is currently the Medical Director at Turning Point addiction treatment facility in North Jersey. She has been involved with the field of addiction medicine, HIV care and Psychiatry for the last 12 years. Her private practice focuses on novel modalities used in treating addiction and dual diagnosis patients, both adolescent and adults.

 

Nancy E. White, Ph.D.

 

Dr. White is the Clinical Director of Unique MindCare in Houston, Texas. She is recognized as an industry leader in the development of a brain based approach to support neurobehavioral wellness. Dr. White has specialized in the diagnosis and treatment of functional brain disorders for more than twenty years. She is a Fellow, past President and Board member of the International Society for Neurofeedback and Research (ISNR), a Certified EEG Fellow of the Biofeedback Certification International Alliance (BCN) and a QEEG Diplomate and member of the Quantitative EEG Certification Board. Dr. White is a licensed Clinical Psychologist in the State of Texas as well as a Licensed Marriage and Family Therapist and Advanced Addictions Counselor.

 

Dr. White is a pioneer in the practical application of neuroscientific research to clinical practice, including the extension of advanced brain based therapies to all psychiatric mood disorders including Post-Traumatic Stress, Autism and Addictions. She is a frequent presenter of her work at conferences, including the American Academy of Anti-Aging Medicine, the International Society for Neurofeedback and Research, the Association for Applied Psychophysiology and Biofeedback, FutureHealth, and the National Academy of Neuropsychology. She also serves as a consulting editor of the Journal of Neurotherapy (Taylor and Francis).

 

Dr. White has dedicated 3 years to the development of the clinical application of the Nexalin Therapy. Her research and clinical data on the use of Nexalin Therapy has been presented at International conferences.

 

Benjamin V. Hu, MD

 

Dr. Hu is currently in private practice, with a specialty in General Ophthalmology, which consists of both medical and surgical aspects including use of lasers, in Parma, Ohio: He is also a member of the Board of Directors and an Advisor to Enlighten Technologies Inc. of Laguna Hills California, a company developing a surgical machine for cataract surgery with newly patented technology.

 

Dr. Hu previously was a member of the NRAGT Board of Advisors, a parent advocacy group trying to increase classes, programs and clubs to challenge the gifted, talented kids of North Royalton, Ohio; a Member of the Board of Advisors of QMS Inc., a company manufacturing and marketing scale control systems and technology to business and industry in Cleveland, Ohio; and Co-Director of Ion-X International, LLC in Huron, Ohio, a company manufacturing, marketing and distributing copper/silver ionization systems and technology to business and industry.

 

Dr. Hu was awarded his Chemical Engineering degree in June, 1979 in conjunction with the MIT School of Chemical Engineering Practice, Cambridge, Massachusetts, with an emphasis on practical problem solving and independent research projects. Dr. Hu was awarded his Doctorate of Medicine in May, 1983 from Case Western Reserve in Cleveland, Ohio, with an emphasis in applied medical research. Dr. Hu did his Post-Doctorate Resident training in ophthalmology at the Kresge Eye Institute, Wayne State University, Detroit, Michigan. He is the co-developer of a PCL implantation technique in the absence of capsular or zonular support. His technical paper won the First Prize in the Kresge Residence Day competition for best research project and presentation.

 

  6  

 

 

Item 3.02 Unregistered Sales of Equity Securities.

 

The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference.

 

These securities were not registered under the Securities Act of 1933, as amended (the “Securities Act”), but qualified for exemption under Section 4(2) of the Securities Act. The securities were exempt from registration under Section 4(2) of the Securities Act because the issuance of such securities by the Company did not involve a “public offering,” as defined in Section 4(2) of the Securities Act, due to the insubstantial number of persons involved in the transaction, size of the offering, manner of the offering and number of securities offered. The Company did not undertake an offering in which it sold a high number of securities to a high number of investors. In addition, these shareholders had the necessary investment intent as required by Section 4(2) of the Securities Act since they agreed to, and received, share certificates bearing a legend stating that such securities are restricted pursuant to Rule 144 of the Securities Act. This restriction ensures that these securities would not be immediately redistributed into the market and therefore not be part of a “public offering.” Based on an analysis of the above factors, we have met the requirements to qualify for exemption under Section 4(2) of the Securities Act.

 

Item 5.01 Changes in Control of Registrant

 

The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference.

 

As more fully described in Item 1.01 above, the Company issued approximately 12,500,000 Shares of the Company’s common stock to the Nexalin Shareholders in exchange for up to approximately 26,000,000 of the issued and outstanding shares of the ordinary shares of Nexalin, together with shares issuable upon exercise of options, which constitutes approximately 51% percent of the currently issued and outstanding shares of the Company’s common stock after the transactions described herein.

 

Related Party Transactions

 

The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference.

 

Randall Letcavage, the Company’s sole officer and director, is also an officer and director, and shareholder of Nexalin. As a result, Mr. Letcavage received shares of common stock pursuant to the Share Exchange Agreement and following such issuance, holds, together with affiliates, approximately 6.5 million shares of common stock, or approximately 12% of the issued and outstanding shares at the Closing Date, and approximately 22% following the issuance of the additional shares reserved for issuance under the Share Exchange Agreement.

 

Item 5.02   Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

 

(a)   Appointment of Directors

 

The disclosures set forth in Item 5.01 above are incorporated by reference into this Item 5.02(a).

 

(b)   Appointment of Officers

 

The disclosures set forth in Item 5.01 above are incorporated by reference into this Item 5.02(b).

 

On September 1, 2017, the Company obtained written consent by the holders of the majority of the voting power of the Company's capital stock approving the adoption of the Company’s 2017 Stock Incentive Plan (the “Plan”). The Plan allows the Board of Directors of the Company to grant incentive stock options, nonqualified stock options and restricted stock awards to officers, directors, employees and consultants of the Company. There are 5,000,000 shares of common stock of the Company reserved for issuance under the Plan.

 

Item 9.01 Financial Statements and Exhibits.

 

(a) Financial Statements of Business Acquired.

 

This Current Report on Form 8-K will be supplemented by amendment to provide the required financial statements not later than 71 days after the date that this Current Report on Form 8-K was required to be filed.

 

  7  

 

 

(b) Pro Forma Financial Information.

 

This Current Report on Form 8-K will be supplemented by amendment to provide the required pro forma financial information not later than 71 days after the date that this Current Report on Form 8-K was required to be filed.

 

(d) Exhibits.

 

Exhibit No.   Description
2.1   Form of Share Exchange Agreement, effective as of September 1, 2017, by and among Legacy Ventures International, Inc., Nexalin Technology Inc. and shareholders of Nexalin Technology Inc.
2.2   Form of Warrant.

 

  8  

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  

  Legacy Ventures International, Inc.
     
Date: September 14, 2017 By: /s/ Randall Letcavage
    Name: Randall Letcavage
    Title:  Chief Executive Officer

 

 

 

9

 

 

Exhibit 2.1

 

 

 

SHARE EXCHANGE AGREEMENT

 

 

by and among

 

 

LEGACY VENTURES INTERNATIONAL, INC.

 

 

NEXALIN TECHNOLOGY, INC.

 

 

and

 

 

THE SHAREHOLDERS OF

NEXALIN TECHNOLOGY , INC.

NAMED HEREIN

 

 

Dated as of September 1, 2017

 

 

 

 

 

 

SHARE EXCHANGE AGREEMENT

 

This SHARE EXCHANGE AGREEMENT (this “ Agreement ”), dated as of September 1, 2017, is by and among Legacy Ventures International, Inc., a Nevada corporation (“ LGYV ”), Nexalin Technology, Inc., a Nevada corporation (“ NEXALIN ”), and the shareholders of NEXALIN (the “ Shareholders ”). Each of the parties to this Agreement is individually referred to herein as a “ Party ” and collectively, as the “ Parties .” Capitalized terms used herein that are not otherwise defined herein shall have the meanings ascribed to them in Annex A hereto.

 

BACKGROUND

 

A.         LGYV is a publicly traded corporation quoted on the OTC Markets (the “OTC”).

 

B.          LGYV has approximately 315,064 shares of common stock issued and outstanding, and no shares of Preferred Stock issued and outstanding. NEXALIN has approximately 51 million shares of common stock issued and outstanding, together with additional shares issuable to service providers and with respect with outstanding options and convertible securities (the “ NEXALIN Stock ”), issued and outstanding, which shares are owned by the Shareholders. The Shareholders are the record and beneficial owner of the number of shares of NEXALIN Stock, or the right to receive such shares, set forth opposite such Shareholder’s name on Annex A hereto.

 

C.          The Shareholders (and certain other stakeholders of the Company) have agreed to transfer all of their shares of NEXALIN Stock, or the right to receive such stock, in exchange for units (the “Units”) consisting of an aggregate of approximately 25,000,000 newly issued shares of the Common Stock, $0.001 par value, of LGYV (the “ LGYV Stock ”) and warrants (the “Warrants”) to purchase an aggregate of approximately 25,000,000 newly issued shares of the Common Stock, $0.001 par value, of LGYV (the “Warrant Shares”). In the aggregate, the shares of LGYV Stock issuable to the Shareholders and consultants will be approximately ninety-nine percent (99%) of the issued and outstanding capital stock of LGYV as of and immediately after the Closing. The Company shall also reserve up to 5 million additional shares for issuance to management, employees and consultants following the Closing in the ordinary course of business pursuant to a stock incentive plan.

 

D.          The Board of Directors of each of LGYV and NEXALIN has determined that it is desirable to effect this plan of reorganization and share exchange.

 

AGREEMENT

 

NOW, THEREFORE, in consideration of the foregoing and the respective representations, warranties, covenants and agreements set forth herein, and intending to be legally bound hereby, the Parties agree as follows:

 

ARTICLE I

Exchange of Shares

 

1.1.        Exchange by the Shareholders. At the Closing, each of the Shareholders shall sell, transfer, convey, assign and deliver to LGYV its NEXALIN Stock free and clear of all Liens in exchange for its pro rata portion of the LGYV Stock and Warrants at the approximate exchange ratio of 0.477 shares of LGYV stock for each share of NEXLAIN stock, together with an equivalent number of Warrants. Approximately 2 million shares of Common Stock will be issued to other stakeholders of the Company in connection with the share exchange transaction. The Warrants will be in substantially the form attached hereto as Exhibit A .

 

 

 

 

1.2.         Closing. The closing (the “ Closing ”) of the transactions contemplated hereby (the “ Transactions ”) shall take place at the offices of Kline Law Group, PC in Irvine, CA commencing at 9:00 a.m. local time on the second business day following the satisfaction or waiver of all conditions to the obligations of the Parties to consummate the Transactions (other than conditions with respect to actions that the respective parties will take at Closing) or such other date and time as the Parties may mutually determine (the “ Closing Date ”).

 

ARTICLE II

Representations and Warranties of the Shareholder

 

Each Shareholder, severally, hereby represents and warrants to LGYV with respect to itself, as follows.

 

2.1.         Good Title. The Shareholder is the record and beneficial owner, and has good title to its NEXALIN Stock, with the right and authority to sell and deliver such NEXALIN Stock. Upon delivery of any certificate or certificates duly assigned, representing the same as herein contemplated and/or upon registering of LGYV as the new owner of such NEXALIN Stock in the share register of NEXALIN, LGYV will receive good title to such NEXALIN Stock, free and clear of all Liens.

 

2.2.         Power and Authority. The Shareholder has the legal power, capacity and authority to execute and deliver this Agreement and each Transaction Document to be delivered by it hereunder and to perform its obligations hereunder and thereunder, and to consummate the Transactions. All acts required to be taken by the Shareholder to enter into this Agreement, to deliver each Transaction Document to which it is a party and to carry out the Transactions have been properly taken. This Agreement constitutes a legal, valid and binding obligation of the Shareholder, enforceable against the Shareholder in accordance with the terms hereof, except as such enforcement is limited by general equitable principles, or by bankruptcy, insolvency and other similar laws affecting the enforcement of creditors’ rights generally.

 

2.3.         No Conflicts. The execution and delivery of this Agreement by the Shareholder and the performance by the Shareholder of its obligations hereunder in accordance with the terms hereof: (a) will not require the consent of any third party or Governmental Entity under any Laws; (b) will not violate any Laws applicable to the Shareholder ; and (c) will not violate or breach any contractual obligation to which the Shareholder is a party.

 

2.4.         Litigation. There is no pending proceeding against the Shareholder that involves the NEXALIN Stock or that challenges, or may have the effect of preventing, delaying or making illegal, or otherwise interfering with, any of the Transactions and, to the knowledge of the Shareholder, no such proceeding has been threatened, and no event or circumstance exists that is reasonably likely to give rise to or serve as a basis for the commencement of any such proceeding.

 

2.5.         No Finder’s Fee. The Shareholder has not created any obligation for any finder’s, investment banker’s or broker’s fee in connection with the Transactions.

 

2.6.         Purchase Entirely for Own Account. The LGYV Stock, Warrants and Warrant Shares (the “Securities”) proposed to be acquired by the Shareholder hereunder will be acquired for investment for its own account, and not with a view to the resale or distribution of any part thereof, and the Shareholder has no present intention of selling or otherwise distributing the Units, except in compliance with applicable securities laws.

 

Legacy Ventures International, Inc.

Nexalin Technology, Inc.

SHARE EXCHANGE AGREEMENT

September 1, 2017

 
  - 2 -  

 

 

2.7.         Available Information. The Shareholder has such knowledge and experience in financial and business matters that it is capable of evaluating the merits and risks of investment in LGYV.

 

2.8.         Non-Registration. The Shareholder understands that the Securities have not been registered under the Securities Act and, if issued in accordance with the provisions of this Agreement, will be issued by reason of a specific exemption from the registration provisions of the Securities Act which depends upon, among other things, the bona fide nature of the investment intent and the accuracy of the Shareholder’s ’s representations as expressed herein. The non-registration shall have no prejudice with respect to any rights, interests, benefits and entitlements attached to the Securities in accordance with LGYV’s charter documents or the laws of its jurisdiction of incorporation.

 

2.9.         Restricted Securities. The Shareholder understands that the Shares are characterized as “restricted securities” under the Securities Act inasmuch as this Agreement contemplates that, if acquired by the Shareholder pursuant hereto, the Shares would be acquired in a transaction not involving a public offering. The issuance of the Shares hereunder have not been registered under the Securities Act or the securities laws of any state of the U.S. and that the issuance of the Securities is being effected in reliance upon an exemption from registration afforded under Section 4(2) of the Securities Act for transactions by an issuer not involving a public offering. The Shareholder further acknowledges that if the Shares are issued to the Shareholder in accordance with the provisions of this Agreement, such Shares may not be resold without registration under the Securities Act or the existence of an exemption therefrom. The Shareholder represents that it is familiar with Rule 144 promulgated under the Securities Act, as presently in effect, and understands the resale limitations imposed thereby and by the Securities Act.

 

2.10.       Accredited Investor. The Shareholder is an “Accredited Investor” within the meaning of Rule 501 under the Securities Act.

 

2.11.       Legends. The Shareholder hereby agrees with LGYV that the Securities will bear the following legend or one that is substantially similar to the following legend:

 

THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE SECURITIES LAWS AND NEITHER SUCH SECURITIES NOR ANY INTEREST THEREIN MAY BE OFFERED, SOLD, PLEDGED, ASSIGNED OR OTHERWISE TRANSFERRED EXCEPT (1) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS OR (2) PURSUANT TO AN AVAILABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS, IN WHICH CASE THE HOLDER MUST, PRIOR TO SUCH TRANSFER, FURNISH TO THE COMPANY AN OPINION OF COUNSEL, WHICH COUNSEL AND OPINION ARE REASONABLY SATISFACTORY TO THE COMPANY, THAT SUCH SECURITIES MAY BE OFFERED, SOLD, PLEDGED, ASSIGNED OR OTHERWISE TRANSFERRED IN THE MANNER CONTEMPLATED PURSUANT TO AN AVAILABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS.

 

Legacy Ventures International, Inc.

Nexalin Technology, Inc.

SHARE EXCHANGE AGREEMENT

September 1, 2017

 
  - 3 -  

 

 

2.12.       Additional Legend; Consent. Additionally, the Securities will bear any legend required by the “blue sky” laws of any state to the extent such laws are applicable to the securities represented by the certificate so legended. The Shareholder consents to LGYV making a notation on its records or giving instructions to any transfer agent of Securities in order to implement the restrictions on transfer of the Shares.

 

ARTICLE III

Representations and Warranties of NEXALIN

 

NEXALIN represents and warrants as follows to LGYV.

 

3.1.         Organization, Standing and Power. NEXALIN and each of its subsidiaries is duly organized, validly existing and in good standing under the laws of the jurisdiction in which it is organized and has the corporate power and authority and possesses all governmental franchises, licenses, permits, authorizations and approvals necessary to enable it to own, lease or otherwise hold its properties and assets and to conduct its businesses as presently conducted, other than such franchises, licenses, permits, authorizations and approvals the lack of which, individually or in the aggregate, has not had and would not reasonably be expected to have a material adverse effect on NEXALIN, a material adverse effect on the ability of NEXALIN to perform its obligations under this Agreement or on the ability of NEXALIN to consummate the Transactions (a “ NEXALIN Material Adverse Effect ”). NEXALIN and each of its subsidiaries is duly qualified to do business in each jurisdiction where the nature of its business or its ownership or leasing of its properties make such qualification necessary except where the failure to so qualify would not reasonably be expected to have a NEXALIN Material Adverse Effect. NEXALIN has delivered to LGYV true and complete copies of the NEXALIN Charter, the NEXALIN Bylaws, and the comparable charter, organizational documents and other constituent NEXALIN Options of each of its subsidiaries, in each case as amended through the date of this Agreement.

 

3.2.         Subsidiaries; Equity Interests. All the outstanding shares of capital stock or equity investments of each subsidiary have been validly issued and are fully paid and nonassessable and are as of the date of this Agreement owned by NEXALIN, by another subsidiary of NEXALIN or by NEXALIN and another subsidiary of NEXALIN, free and clear of all Liens. Except for its interests in its subsidiaries, NEXALIN does not as of the date of this Agreement own, directly or indirectly, any capital stock, membership interest, partnership interest, joint venture interest or other equity interest in any person.

 

3.3.         Capital Structure. The authorized capital stock of NEXALIN consists of 100,000,000 shares of common stock. As of the date hereof, 51,211,334 shares of common stock are issued and outstanding, including shares issuable with respect to outstanding options and convertible debentures. No shares of capital stock or other voting securities of NEXALIN are issued, reserved for issuance or outstanding. NEXALIN is the sole record and beneficial owner of all of the issued and outstanding capital stock of each of its subsidiaries. All outstanding shares of the capital stock of NEXALIN and each of its subsidiaries are duly authorized, validly issued, fully paid and nonassessable and not subject to or issued in violation of any purchase option, call option, right of first refusal, preemptive right, subscription right or any similar right under any provision of the law of organization, the NEXALIN Charter, the NEXALIN Bylaws or any Contract to which NEXALIN is a party or otherwise bound. There are not any bonds, debentures, notes or other indebtedness of NEXALIN or any of its subsidiaries having the right to vote (or convertible into, or exchangeable for, securities having the right to vote) on any matters on which holders of NEXALIN’s capital stock or the capital stock of any of its subsidiaries may vote (“ Voting NEXALIN Debt ”). As of the date of this Agreement, there are not any options, warrants, rights, convertible or exchangeable securities, “phantom” stock rights, stock appreciation rights, stock-based performance units, commitments, Contracts, arrangements or undertakings of any kind to which NEXALIN or any of its subsidiaries is a party or by which any of them is bound (a) obligating NEXALIN or any of its subsidiaries to issue, deliver or sell, or cause to be issued, delivered or sold, additional shares of capital stock or other equity interests in, or any security convertible or exercisable for or exchangeable into any capital stock of or other equity interest in, NEXALIN or any of its subsidiaries or any Voting NEXALIN Debt, (b) obligating NEXALIN or any of its subsidiaries to issue, grant, extend or enter into any such option, warrant, call, right, security, commitment, Contract, arrangement or undertaking or (c) that give any person the right to receive any economic benefit or right similar to or derived from the economic benefits and rights occurring to holders of the capital stock of NEXALIN or of any of its subsidiaries. As of the date of this Agreement, there are not any outstanding contractual obligations of NEXALIN to repurchase, redeem or otherwise acquire any shares of capital stock of NEXALIN

 

Legacy Ventures International, Inc.

Nexalin Technology, Inc.

SHARE EXCHANGE AGREEMENT

September 1, 2017

 
  - 4 -  

 

 

3.4.        Authority; Execution and Delivery; Enforceability. NEXALIN has all requisite corporate power and authority to execute and deliver this Agreement and to consummate the Transactions. The execution and delivery by NEXALIN of this Agreement and the consummation by NEXALIN of the Transactions have been duly authorized and approved by the Board of Directors of NEXALIN and no other corporate proceedings on the part of NEXALIN are necessary to authorize this Agreement and the Transactions. When executed and delivered, this Agreement will be enforceable against NEXALIN in accordance with its terms., except as such enforcement is limited by general equitable principles, or by bankruptcy, insolvency and other similar laws affecting the enforcement of creditors’ rights generally.

 

3.5.         No Conflicts; Consents. The execution and delivery by NEXALIN of this Agreement does not, and the consummation of the Transactions and compliance with the terms hereof will not, conflict with, or result in any violation of or default (with or without notice or lapse of time, or both) under, or give rise to a right of termination, cancellation or acceleration of any obligation or to loss of a material benefit under, or result in the creation of any Lien upon any of the properties or assets of NEXALIN or any of its subsidiaries under, any provision of (i) the NEXALIN Charter, the NEXALIN Bylaws or the comparable charter or organizational documents of any of its subsidiaries, (ii) any material Contract to which NEXALIN or any of its subsidiaries is a party or by which any of their respective properties or assets is bound or (iii) any material judgment, order or decree or material Law applicable to NEXALIN or any of its subsidiaries or their respective properties or assets, other than, in the case of clauses (ii) and (iii) above, any such items that, individually or in the aggregate, have not had and would not reasonably be expected to have a NEXALIN Material Adverse Effect.

 

3.6.         Compliance with Applicable Laws. Except for any required filings under applicable “Blue Sky” or state securities commissions, no Consent of, or registration, declaration or filing with, or permit from, any Governmental Entity is required to be obtained or made by or with respect to NEXALIN or any of its subsidiaries in connection with the execution, delivery and performance of this Agreement or the consummation of the Transactions. NEXALIN and each of its subsidiaries have conducted their business and operations in compliance with all applicable Laws, except for instances of noncompliance that, individually and in the aggregate, have not had and would not reasonably be expected to have a NEXALIN Material Adverse Effect.

 

3.7.         Brokers. No broker, investment banker, financial advisor or other person is entitled to any broker’s, finder’s, financial advisor’s or other similar fee or commission in connection with the Transactions based upon arrangements made by or on behalf of NEXALIN or any of its subsidiaries.

 

Legacy Ventures International, Inc.

Nexalin Technology, Inc.

SHARE EXCHANGE AGREEMENT

September 1, 2017

 
  - 5 -  

 

 

3.8.         Investment Company. NEXALIN is not, and is not an affiliate of, and immediately following the Closing will not have become, an “investment company” within the meaning of the Investment Company Act of 1940, as amended.

 

3.9.         Foreign Corrupt Practices. Neither NEXALIN, nor any of its subsidiaries, nor, to NEXALIN’s knowledge, any director, officer, agent, employee or other person acting on behalf of NEXALIN or any of its subsidiaries has, in the course of its actions for, or on behalf of, NEXALIN (a) used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expenses relating to political activity; (b) made any direct or indirect unlawful payment to any foreign or domestic government official or employee from corporate funds; ; or (d) made any unlawful bribe, rebate, payoff, influence payment, kickback or other unlawful payment to any foreign or domestic government official or employee.

 

3.10.       Disclosure. All disclosure provided to LGYV regarding NEXALIN, its business and the Transactions, furnished by or on behalf of NEXALIN (including NEXALIN’s representations and warranties set forth in this Agreement) is true and correct and does not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading.

 

3.11.       No Additional Agreements. NEXALIN does not have any agreement or understanding with the Shareholder with respect to the Transactions other than as specified in this Agreement.

 

ARTICLE IV

Representations and Warranties of LGYV

 

LGYV represents and warrants as follows to the Shareholders and NEXALIN.

 

4.1.         Organization, Standing and Power. LGYV is duly organized, validly existing and in good standing under the laws of the State of Nevada and has full corporate power and authority and possesses all governmental franchises, licenses, permits, authorizations and approvals necessary to enable it to own, lease or otherwise hold its properties and assets and to conduct its businesses as presently conducted, other than such franchises, licenses, permits, authorizations and approvals the lack of which, individually or in the aggregate, has not had and would not reasonably be expected to have a material adverse effect on LGYV, a material adverse effect on the ability of LGYV to perform its obligations under this Agreement or on the ability of LGYV to consummate the Transactions (a “LGYV Material Adverse Effect ”). LGYV is duly qualified to do business in each jurisdiction where the nature of its business or its ownership or leasing of its properties makes such qualification necessary and where the failure to so qualify would reasonably be expected to have a LGYV Material Adverse Effect. LGYV has delivered to NEXALIN true and complete copies of the LGYV Charter and the LGYV Bylaws, as amended through date of this Agreement.

 

4.2.         Subsidiaries. LGYV, has no subsidiaries.

 

Legacy Ventures International, Inc.

Nexalin Technology, Inc.

SHARE EXCHANGE AGREEMENT

September 1, 2017

 
  - 6 -  

 

 

4.3.         Capital Structure. The authorized capital stock of LGYV consists of 100,000,000 shares of common stock and 10,000,000 shares of preferred stock. As of the date hereof, 315,064 shares of common stock are issued and outstanding, and no shares of preferred stock are outstanding. No shares of capital stock or other voting securities of LGYV are issued, reserved for issuance or outstanding, other than up to 5 million shares reserved for issuance pursuant to the proposed stock incentive plan. There are not any bonds, debentures, notes or other indebtedness of NEXALIN or any of its subsidiaries having the right to vote (or convertible into, or exchangeable for, securities having the right to vote) on any matters on which holders of LGYV’s capital stock or the capital stock of any of its subsidiaries may vote (“ Voting LGYV Debt ”). As of the date of this Agreement, there are not any options, warrants, rights, convertible or exchangeable securities, “phantom” stock rights, stock appreciation rights, stock-based performance units, commitments, Contracts, arrangements or undertakings of any kind to which LGYV or any of its subsidiaries is a party or by which any of them is bound (a) obligating LGYV or any of its subsidiaries to issue, deliver or sell, or cause to be issued, delivered or sold, additional shares of capital stock or other equity interests in, or any security convertible or exercisable for or exchangeable into any capital stock of or other equity interest in, LGYV or any of its subsidiaries or any Voting LGYV Debt, (b) obligating LGYV or any of its subsidiaries to issue, grant, extend or enter into any such option, warrant, call, right, security, commitment, Contract, arrangement or undertaking or (c) that give any person the right to receive any economic benefit or right similar to or derived from the economic benefits and rights occurring to holders of the capital stock of LGYV or of any of its subsidiaries, other than three outstanding convertible notes in the aggregate principal amount of $520,000, which are convertible, in the aggregate, into 25% of the outstanding shares of common stock of LGYV immediately following such conversion. As of the date of this Agreement, there are not any outstanding contractual obligations of LGYV to repurchase, redeem or otherwise acquire any shares of capital stock of LGYV.

  

4.4.         Authority; Execution and Delivery; Enforceability. The execution and delivery by LGYV of this Agreement and the consummation by LGYV of the Transactions have been duly authorized and approved by the Board of Directors of LGYV and the holders of a majority of its capital stock and no other corporate proceedings on the part of LGYV are necessary to authorize this Agreement and the Transactions. This Agreement constitutes a legal, valid and binding obligation of LGYV, enforceable against LGYV in accordance with the terms hereof.

 

4.5.         No Conflicts; Consents. The execution and delivery by LGYV of this Agreement does not, and the consummation of Transactions and compliance with the terms hereof will not, contravene, conflict with or result in any violation of or default (with or without notice or lapse of time, or both) under, or give rise to a right of termination, cancellation or acceleration of any obligation or to loss of a material benefit under, or to increased, additional, accelerated or guaranteed rights or entitlements of any person under, or result in the creation of any Lien upon any of the properties or assets of LGYV under, any provision of (i) the LGYV Charter or LGYV Bylaws, (ii) any material Contract to which LGYV is a party or by which any of its properties or assets is bound or (iii) subject to the filings and other matters referred to in Section 4.6(b), any material Order or material Law applicable to LGYV or its properties or assets, other than, in the case of clauses (ii) and (iii) above, any such items that, individually or in the aggregate, have not had and would not reasonably be expected to have a LGYV Material Adverse Effect.

 

4.6.         Disclosure. All disclosure provided to the Shareholder regarding LGYV, its business and the Transactions, furnished by or on behalf of LGYV (including LGYV’s representations and warranties set forth in this Agreement) is true and correct and does not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading.

 

4.7.         No Undisclosed Events, Liabilities, Developments or Circumstances. No event, liability, development or circumstance has occurred or exists, or is contemplated to occur with respect to LGYV, its subsidiaries or their respective businesses, properties, prospects, operations or financial condition, that would be required to be disclosed by LGYV under applicable securities laws on a registration statement on Form S-1 filed with the SEC relating to an issuance and sale by LGYV of its common stock and which has not been publicly announced.

 

4.8.         No Additional Agreements. LGYV does not have any agreement or understanding with the Shareholder with respect to the Transactions other than as specified in this Agreement.

 

Legacy Ventures International, Inc.

Nexalin Technology, Inc.

SHARE EXCHANGE AGREEMENT

September 1, 2017

 
  - 7 -  

 

 

ARTICLE V
Conditions to Closing

 

5.1.         LGYV Conditions Precedent. The obligations of the Shareholders and NEXALIN to enter into and complete the Closing are subject, at the option of the Shareholders (acting by majority thereof) and NEXALIN, to the fulfillment on or prior to the Closing Date of the following conditions, any one or more of which may be waived by NEXALIN and the Shareholder in writing.

 

(a)            Representations and Covenants . The representations and warranties of LGYV contained in this Agreement shall be true in all material respects on and as of the Closing Date with the same force and effect as though made on and as of the Closing Date. LGYV shall have performed and complied in all material respects with all covenants and agreements required by this Agreement to be performed or complied with by LGYV on or prior to the Closing Date.

 

(b)            Litigation . No action, suit or proceeding shall have been instituted before any court or governmental or regulatory body or instituted or threatened by any governmental or regulatory body to restrain, modify or prevent the carrying out of the Transactions or to seek damages or a discovery order in connection with such Transactions, or which has or may have, in the reasonable opinion of NEXALIN or the Shareholder, a materially adverse effect on the assets, properties, business, operations or condition (financial or otherwise) of LGYV.

 

(c)            Consents . All material consents, waivers, approvals, authorizations or orders required to be obtained, and all filings required to be made, by LGYV for the authorization, execution and delivery of this Agreement and the consummation by it of the Transactions shall have been obtained and made by LGYV, except where the failure to receive such consents, waivers, approvals, authorizations or orders or to make such filings would not have a LGYV Material Adverse Effect.

 

(d)            Satisfactory Completion of Due Diligence . NEXALIN and the Shareholder shall have completed their legal, accounting and business due diligence of LGYV and the results thereof shall be satisfactory to NEXALIN and the Shareholder in their sole and absolute discretion.

 

(e)            Issuance of Shares and Warrants . At or within five (5) business days following the Closing, LGYV shall deliver to the Shareholder a certificate representing the new shares of LGYV Stock and the Warrants will be issued to such Shareholder.

 

(f)            Such other documents as NEXALIN may reasonably request for the purpose of facilitating the consummation of the Transactions.

 

5.2.         NEXALIN and Shareholders Conditions Precedent. The obligations of LGYV to enter into and complete the Closing is subject, at the option of LGYV, to the fulfillment on or prior to the Closing Date of the following conditions, any one or more of which may be waived by LGYV in writing.

 

(a)            Representations and Covenants . The representations and warranties of the Shareholders and NEXALIN contained in this Agreement shall be true in all material respects on and as of the Closing Date with the same force and effect as though made on and as of the Closing Date. The Shareholder and NEXALIN shall have performed and complied in all material respects with all covenants and agreements required by this Agreement to be performed or complied with by the Shareholder and NEXALIN on or prior to the Closing Date.

 

Legacy Ventures International, Inc.

Nexalin Technology, Inc.

SHARE EXCHANGE AGREEMENT

September 1, 2017

 
  - 8 -  

 

 

(b)            Litigation . No action, suit or proceeding shall have been instituted before any court or governmental or regulatory body or instituted or threatened by any governmental or regulatory body to restrain, modify or prevent the carrying out of the Transactions or to seek damages or a discovery order in connection with such Transactions, or which has or may have, in the reasonable opinion of LGYV, a materially adverse effect on the assets, properties, business, operations or condition (financial or otherwise) of NEXALIN.

 

(c)            Consents . All material consents, waivers, approvals, authorizations or orders required to be obtained, and all filings required to be made, by the Shareholder or NEXALIN for the authorization, execution and delivery of this Agreement and the consummation by them of the Transactions, shall have been obtained and made by the Shareholder or NEXALIN, except where the failure to receive such consents, waivers, approvals, authorizations or orders or to make such filings would not have an NEXALIN Material Adverse Effect.

 

(d)            Satisfactory Completion of Due Diligence . LGYV shall have completed its legal, accounting and business due diligence of NEXALIN and the Shareholder and the results thereof shall be satisfactory to LGYV in its sole and absolute discretion.

 

(e)            Share Transfer Documents . The Shareholder shall have delivered to LGYV the original certificate(s) representing its NEXALIN Stock, accompanied by a duly executed stock transfer power for transfer by the Shareholder of its NEXALIN Stock to LGYV.

 

ARTICLE VI

Covenants

 

6.1.         Blue Sky Laws. LGYV shall take any action (other than qualifying to do business in any jurisdiction in which it is not now so qualified) required to be taken under any applicable state securities laws in connection with the issuance of the Securities in connection with this Agreement.

 

6.2.         Public Announcements. LGYV and NEXALIN will consult with each other before issuing, and provide each other the opportunity to review and comment upon, any press releases or other public statements with respect to this Agreement and the Transactions and shall not issue any such press release or make any such public statement prior to such consultation, except as may be required by applicable Law, court process or by obligations pursuant to any listing agreement with any national securities exchanges.

 

6.3.         Fees and Expenses. All fees and expenses incurred in connection with this Agreement shall be paid by the Party incurring such fees or expenses, whether or not this Agreement is consummated.

 

6.4.         Continued Efforts. Each Party shall use commercially reasonable efforts to (a) take all action reasonably necessary to consummate the Transactions, and (b) take such steps and do such acts as may be necessary to keep all of its representations and warranties true and correct as of the Closing Date with the same effect as if the same had been made, and this Agreement had been dated, as of the Closing Date.

 

Legacy Ventures International, Inc.

Nexalin Technology, Inc.

SHARE EXCHANGE AGREEMENT

September 1, 2017

 
  - 9 -  

 

 

6.5          Sale Restriction.

 

(a)          Each Shareholder hereby agrees that for the period beginning on the date hereof and ending twelve months (12) months from the FINRA Approval, as defined below (the “Restricted Period”), the Shareholder will not offer, pledge, sell, contract to sell, sell any option or contract to purchase, lend, transfer or otherwise dispose of any shares or any options, warrants or other rights to purchase shares or any other security of the Company which Shareholder owns or has a right to acquire as of the date hereof (collectively, the “Lockup Shares”). Any subsequent issuance to and/or acquisition by Shareholder of shares or options or instruments convertible into shares will be subject to the provisions of this Agreement. Notwithstanding the foregoing restrictions on transfer, the Shareholder may, at any time and from time to time during the Restricted Period, transfer the shares (i) as bona fide gifts or transfers by will or intestacy, (ii) to any trust for the direct or indirect benefit of the undersigned or the immediate family of the Shareholder, provided that any such transfer shall not involve a disposition for value, (iii) to a partnership which is the general partner of a partnership of which the Shareholder is a general partner, provided, that, in the case of any gift or transfer described in clauses (i), (ii) or (iii), each donee or transferee agrees in writing to be bound by the terms and conditions contained herein in the same manner as such terms and conditions apply to the undersigned. For purposes hereof, “immediate family” means any relationship by blood, marriage or adoption, not more remote than first cousin. The term “FINRA Approval” means the date of approval by FINRA of the Company’s name change and issuance of a new trading symbol.

 

(b)          Beginning on the first day of the twelfth (12th) month after FINRA Approval, the restrictions on sale of the Lockup Shares set forth herein shall terminate with respect to twenty (20) percent of the Lockup Shares, and on each month thereafter the restrictions with respect to an additional ten (10) percent of the original amount of the Lockup Shares will terminate; such that after nine (9) months all Lockup Shares will be free of the restrictions herein.

 

(c)          During the Restricted Period, the Shareholder shall retain all rights of ownership in the Lockup Shares, including, without limitation, voting rights and the right to receive any dividends that may be declared in respect thereof.

 

(d)          The Company is hereby authorized and required to disclose the existence of this Agreement to its transfer agent. The Company and its transfer agent are hereby authorized and required to decline to make any transfer of the common stock if such transfer would constitute a violation or breach of this Agreement and/or the Purchase Agreement.

 

ARTICLE VII
Miscellaneous

 

7.1.         Notices. All notices, requests, claims, demands and other communications under this Agreement shall be in writing and shall be deemed given upon receipt by the Parties at the addresses set forth on the signature page hereof (or at such other address for a Party as shall be specified by like notice):

 

7.2.         Amendments; Waivers; No Additional Consideration. No provision of this Agreement may be waived or amended except in a written instrument signed by NEXALIN, LGYV and the Shareholder.

 

7.5.         Remedies. In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, the Shareholder, LGYV and NEXALIN will be entitled to specific performance under this Agreement. The Parties agree that monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations described in the foregoing sentence and hereby agrees to waive in any action for specific performance of any such obligation the defense that a remedy at law would be adequate.

 

Legacy Ventures International, Inc.

Nexalin Technology, Inc.

SHARE EXCHANGE AGREEMENT

September 1, 2017

 
  - 10 -  

 

 

7.6.         Severability. If any term or other provision of this Agreement is invalid, illegal or incapable of being enforced by any rule or Law, or public policy, all other conditions and provisions of this Agreement shall nevertheless remain in full force and effect so long as the economic or legal substance of the Transactions is not affected in any manner materially adverse to any Party. Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the Parties shall negotiate in good faith to modify this Agreement so as to effect the original intent of the Parties as closely as possible in an acceptable manner to the end that the Transactions are fulfilled to the extent possible.

 

7.7.         Counterparts; Facsimile Execution. This Agreement may be executed in one or more counterparts, all of which shall be considered one and the same agreement and shall become effective when one or more counterparts have been signed by each of the Parties and delivered to the other Parties. Facsimile execution and delivery of this Agreement is legal, valid and binding for all purposes.

 

7.8.         Entire Agreement; Third Party Beneficiaries. This Agreement, together with the Rescission Agreement (a) constitutes the entire agreement and supersede all prior agreements and understandings, both written and oral, among the Parties with respect to the Transactions and (b) are not intended to confer upon any person other than the Parties any rights or remedies.

 

7.9.         Governing Law. This Agreement shall be governed by, and construed in accordance with, the laws of the State of California, regardless of the laws that might otherwise govern under applicable principles of conflicts of laws thereof, except to the extent the laws of Nevada are mandatorily applicable to the Transactions.

 

[ Signature Page Follows ]

 

Legacy Ventures International, Inc.

Nexalin Technology, Inc.

SHARE EXCHANGE AGREEMENT

September 1, 2017

 
  - 11 -  

 

 

IN WITNESS WHEREOF, the parties hereto have caused this Share Exchange Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.

 

  LEGACY VENTURES INTERNATIONAL, INC.
   
  By:  
  Name: Randall Letcavage
  Title: CEO
   
  NEXALIN TECHNOLOGY, INC.
   
  By:  
  Name:   
  Title:  
   
  SHAREHOLDERS:
   
  By:  
  Name:  
  Number of Nexalin Shares: ______________

 

[ Signature Page to Share Exchange Agreement ]

[ This Agreement may be executed in one or more counterparts ]

 

 

Legacy Ventures International, Inc.

Nexalin Technology, Inc.

SHARE EXCHANGE AGREEMENT

September 1, 2017

 
  - 12 -  

 

 

ANNEX A

Definitions

 

Action ” means any action, suit, inquiry, notice of violation, proceeding (including any partial proceeding such as a deposition) or investigation pending or threatened in writing before or by any court, arbitrator, governmental or administrative agency, regulatory authority (federal, state, county, local or foreign), stock market, stock exchange or trading facility.

 

Code ” means the Internal Revenue Code of 1986, as amended.

 

Consent ” means any material consent, approval, license, permit, order or authorization.         

 

Contract ” means any contract, lease, license, indenture, note, bond, agreement, permit, concession, franchise or other instrument.

 

Exchange Act ” means the Securities Exchange Act of 1934, as amended.

 

GAAP ” means United States generally accepted accounting principles.

 

Governmental Entity ” means any federal, state, local or foreign government or any court of competent jurisdiction, administrative agency or commission or other governmental authority or instrumentality, domestic or foreign.

 

Intellectual Property Right ” means any patent, patent right, trademark, trademark right, trade name, trade name right, service mark, service mark right, copyright and other proprietary intellectual property right and computer program.

 

Law ” means any statute, law, ordinance, rule, regulation, order, writ, injunction, judgment, or decree.

 

Lien ” means any lien, security interest, pledge, equity and claim of any kind, voting trust, stockholder agreement and other encumbrance.

 

LGYV Bylaws ” means the Bylaws of LGYV, as amended to the date of this Agreement.

 

LGYV Charter ” means the Articles of Incorporation of LGYV, as amended to the date of this Agreement.

 

NEXALIN Bylaws ” means the Bylaws of NEXALIN, as amended to the date of this Agreement.

 

NEXALIN Charter ” means the Articles of Incorporation of NEXALIN, as amended to the date of this Agreement.

 

SEC ” means the Securities and Exchange Commission.

 

Securities Act ” means the Securities Act of 1933, as amended.

 

Taxes ” means all forms of taxation, whenever created or imposed, and whether of the United States or elsewhere, and whether imposed by a local, municipal, governmental, state, foreign, federal or other Governmental Entity, or in connection with any agreement with respect to Taxes, including all interest, penalties and additions imposed with respect to such amounts.

 

Tax Return ” means all federal, state, local, provincial and foreign Tax returns, declarations, statements, reports, schedules, forms and information returns and any amended Tax return relating to Taxes.

 

Transaction Documents ” means this Agreement and any other documents or agreements executed in connection with the Transactions.

 

  - 13 -  

Exhibit 2.2

 

NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS DOCUMENT NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL (WHICH COUNSEL SHALL BE SELECTED BY THE HOLDER AND REASONABLY APPROVED BY THE COMPANY), IN A GENERALLY ACCEPTABLE FORM, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD PURSUANT TO RULE 144 OR RULE 144A UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.

 

COMMON STOCK PURCHASE WARRANT

  

Holder:____________________________________
Number of shares:____________________________ (one shares per Unit (as defined in the Share Exchange Agreement, dated September 1, 2017) acquired)

 

Issue Date: September 1, 2017

 

Exercise Price per Share: Set forth in Section 6

 

Expiration Date: September 1, 2019

(or such later date as shall be determined

pursuant to the introductory paragraphs below)

 

FOR VALUE RECEIVED, Legacy Ventures International, Inc., a Nevada corporation (the “ Company ”), hereby certifies that ______________________________, or its registered assigns (the “ Warrant Holder ”), is entitled, subject to the terms set forth below, to purchase from the Company ________________________________ (__________) shares (the “ Warrant Shares ”) of common stock (the “ Common Stock ”), of the Company at the exercise price set forth in Section 6 (the “ Exercise Price ”), at any time and from time to time beginning twelve (12) months after the date hereof and through and including 5:00 p.m. Los Angeles time on the Expiration Date.

 

The “ Expiration Date ” shall mean the later of (i) September 1, 2019, or (ii) if the Company issues any Additional Warrants, the latest expiration date of any Additional Warrant issued. The term “ Additional Warrants ” shall mean warrants issued by the Company after the date hereof in connection with any investment by the Company which is made on substantially similar terms as the investment made in connection with this transaction (taking into account the size and scope of such issuances related to this transaction).

  

 

 

 

This Warrant is subject to the following terms and conditions:

 

1.             Warrant Records . The Company shall record this Warrant upon records to be maintained by the Company for that purpose (the “ Warrant Register ”), in the name of the record Warrant Holder hereof from time to time. The Company may deem and treat the registered Warrant Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or nay distribution to the Warrant Holder, and for all other purposes, and the Company shall not be affected by notice to the contrary.

 

2.             Investment Representation . The Warrant Holder by accepting this Warrant represents that the Warrant Holder is acquiring this Warrant for its own account or the account of an affiliate for investment purposes and not with the view to any offering or distribution and that the Warrant Holder will not sell or otherwise dispose of this Warrant or the underlying Warrant Shares in violation of applicable securities laws. The Warrant Holder acknowledges that the certificates representing any Warrant Shares will bear a legend indicating that they have not been registered under the United States Securities Act of 1933, as amended (the “ 1933 Act ”) and may not be sold by the Warrant Holder except pursuant to an effective registration statement or pursuant to an exemption from registration requirements of the 1933 Act and in accordance with federal and state securities laws. If this Warrant was acquired by the Warrant Holder pursuant to the exemption from the registration requirements of the 1933 Act afforded by Regulation S thereunder, the Warrant Holder acknowledges and covenants that this Warrant may not be exercised by or on behalf of a Person during the one year distribution compliance period (as defined in Regulation S) following the date hereof. “ Person ” means an individual, partnership, firm, limited liability company, trust, joint venture, association, corporation, or any other legal entity.

 

3.             Validity of Warrant and Issue of Shares . The Company represents and warrants that this Warrant has been duly authorized and validly issued and warrants and agrees that all of Common Stock that may be issued upon the exercise of the rights represented by this Warrant will, when issued upon such exercise, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges with respect to the issue thereof. The Company further warrants and agrees that during the period within which the rights represented by this Warrant may be exercised, the Company will at all times have authorized and reserved a sufficient number of Common Stock to provide for the exercise of the rights represented by this Warrant.

 

4.            Registration of Transfers and Exchange of Warrants .

 

a.             Subject to compliance with the legend set forth on the face of this Warrant, the Company shall register the transfer of any portion of this Warrant in the Warrant Register, upon surrender of this Warrant with the Form of Assignment attached hereto duly completed and signed, to the Company at the office specified in or pursuant to Section 9. Upon any such registration or transfer, a new warrant to purchase Common Stock, in substantially the form of this Warrant (any such new warrant, a “ New Warrant ”), evidencing the portion of this Warrant so transferred shall be issued to the transferee and a New Warrant evidencing the remaining portion of this Warrant not so transferred, if any, shall be issued to the transferring Warrant Holder. The acceptance of the New Warrant by the transferee thereof shall be deemed the acceptance of such transferee of all of the rights and obligations of a Warrant Holder of a Warrant.

 

  2  

 

 

b.             This Warrant is exchangeable, upon the surrender hereof by the Warrant Holder to the office of the Company specified in or pursuant to Section 9 for one or more New Warrants, evidencing in the aggregate the right to purchase the number of Warrant Shares which may then be purchased hereunder. Any such New Warrant will be dated the date of such exchange.

 

5.            Exercise Price; Exercise of Warrants .

 

a.             This Warrant entitles the Holder to purchase the number of Warrant Shares set forth herein at the exercise price set forth below (the “ Exercise Price ”), subject to adjustment as described herein:

 

  Date of Exercise:   Exercise Price:  
  12 months and 1 day to 18 months from Issue Date   $ 1.50  
  18 months and 1 day to 18 months from Issue Date   $ 1.75  

 

b.             Exercise of this Warrant shall be made upon surrender of this Warrant with the Form of Election to Purchase attached hereto duly completed and signed to the Company, at its address set forth in Section 9. Subject to Section 5(b) below, payment upon exercise may be made at the written option of the Warrant Holder either in cash, wire transfer or by certified or official bank check payable to the order of the Company equal to the applicable aggregate purchase price, for the number of Warrant Shares specified in such form (as such exercise number shall be adjusted to reflect any adjustment in the total number of Warrant Shares issuable to the Warrant Holder per the terms of this Warrant) and the Warrant Holder shall thereupon be entitled to receive the number of duly authorized, validly issued, fully-paid and non-assessable Warrant Shares determined as provided herein.

 

c.             If at any time during the period following the Issue Date and ending on the Expiration Date, the closing price (as quoted by the OTC Markets or other principal trading market, if applicable) of one share of Common Stock is greater than $3.00 (as adjusted to the date of such calculation) for thirty (30) consecutive trading days, then the Company shall have thirty (30) days to provide written notice to the Holder (in accordance with the notice provisions of the Share Exchange Agreement) of adjustment of the Expiration Date to a date not less than fifteen (15) days after the date of such notice. The Holder may, following such notice, exercise this Warrant at the then applicable Exercise Price until the adjusted Expiration Date; provided that if such Expiration Date is adjusted to a date twelve months or less after the Issue Date, then the Exercise Price will be $1.50 per share.

 

d.             The Company shall promptly (but in no event later than five (5) business days after the Date of Exercise as defined herein) issue or cause to be issued and cause to be delivered to or upon the written order of the Warrant Holder and in such name or names as the Warrant Holder may designate (subject to the restrictions on transfer described in the legend set forth on the face of this Warrant), a certificate for the Warrant Shares issuable upon such exercise, with such restrictive legend as required by the 1933 Act, as applicable. Any person so designated by the Warrant Holder to receive Warrant Shares shall be deemed to have become holder of record of such Warrant Shares as of the Date of Exercise of this Warrant.

 

  3  

 

 

e.             A “ Date of Exercise ” means the date on which the Company shall have received (i) this Warrant (or any New Warrant, as applicable), with the Form of Election to Purchase attached hereto (or attached to such New Warrant) appropriately completed and duly signed, and (ii) payment of the Exercise Price for the number of Warrant Shares so indicated by the Warrant Holder to be purchased.

 

f.              This Warrant shall be exercisable at any time and from time to time for such number of Warrant Shares as is indicated in the attached Form of Election To Purchase. If less than all of the Warrant Shares which may be purchased under this Warrant are exercised at any time, the Company shall issue or cause to be issued, at its expense, a New Warrant evidencing the right to purchase the remaining number of Warrant Shares for which no exercise has been evidenced by this Warrant.

 

6.             Adjustment of Exercise Price and Number of Shares . The character of the shares of stock or other securities at the time issuable upon exercise of this Warrant and the Exercise Price therefor, are subject to adjustment upon the occurrence of the following events:

 

a.              Adjustment for Stock Splits, Stock Dividends, Recapitalizations, Etc. The Exercise Price of this Warrant and the number of shares of Common Stock or other securities at the time issuable upon exercise of this Warrant shall be appropriately adjusted to reflect any stock dividend, stock split, combination of shares, reclassification, recapitalization or other similar event affecting the number of outstanding shares of stock or securities.

 

b.              Adjustment for Reorganization, Consolidation, Merger, Etc. In case of any consolidation or merger of the Company with or into any other corporation, entity or person, or any other corporate reorganization, in which the Company shall not be the continuing or surviving entity of such consolidation, merger or reorganization (any such transaction being hereinafter referred to as a “ Reorganization ”), then, in each case, the holder of this Warrant, on exercise hereof at any time after the consummation or effective date of such Reorganization (the “ Effective Date ”), shall receive, in lieu of the shares of stock or other securities at any time issuable upon the exercise of the Warrant issuable on such exercise prior to the Effective Date, the stock and other securities and property (including cash) to which such holder would have been entitled upon the Effective Date if such holder had exercised this Warrant immediately prior thereto (all subject to further adjustment as provided in this Warrant).

 

c.              Certificate as to Adjustments . In case of any adjustment or readjustment in the price or kind of securities issuable on the exercise of this Warrant, the Company will promptly give written notice thereof to the holder of this Warrant in the form of a certificate, certified and confirmed by the Board of Directors of the Company, setting forth such adjustment or readjustment and showing in reasonable detail the facts upon which such adjustment or readjustment is based.

 

  4  

 

 

7.             Fractional Shares . The Company shall not be required to issue or cause to be issued fractional Warrant Shares on the exercise of this Warrant. The number of full Warrant Shares that shall be issuable upon the exercise of this Warrant shall be computed on the basis of the aggregate number of Warrants Shares purchasable on exercise of this Warrant so presented. If any fraction of a Warrant Share would, except for the provisions of this Section 7, be issuable on the exercise of this Warrant, the Company shall, at its option, (i) pay an amount in cash equal to the Exercise Price multiplied by such fraction or (ii) round the number of Warrant Shares issuable, up to the next whole number.

 

8.             Notice . All notices, demands, requests, consents, approvals, and other communications required or permitted hereunder shall be in writing and, unless otherwise specified herein, shall be (i) personally served, (ii) deposited in the mail, registered or certified, return receipt requested, postage prepaid, (iii) delivered by reputable air courier service with charges prepaid, or (iv) transmitted by hand delivery or facsimile, addressed as set forth in the preamble paragraph hereto or to such other address as such party shall have specified most recently by written notice. Any notice or other communication required or permitted to be given hereunder shall be deemed effective (a) upon hand delivery at the address designated in the preamble paragraph hereto (if delivered on a business day during normal business hours where such notice is to be received), or the first business day following such delivery (if delivered other than on a business day during normal business hours where such notice is to be received) or (b) on the second business day following the date of mailing by express courier service, fully prepaid, addressed to such address, or upon actual receipt of such mailing, whichever shall first occur.

 

10.          Resale Restrictions .

 

a.             Subscriber hereby agrees that for the period beginning on the date hereof and ending eighteen (18) months from the Issue Date, or six (6) months after the Date of Exercise, whichever is longer (the “Lockup Period”), the Subscriber will not offer, pledge, sell, contract to sell, sell any option or contract to purchase, lend, transfer or otherwise dispose of any shares or any options, warrants or other rights to purchase shares or any other security of the Company which Subscriber owns or has a right to acquire as of the date hereof (collectively, the “Lockup Shares”). Any subsequent issuance to and/or acquisition by Subscriber of shares or options or instruments convertible into shares will be subject to the provisions of this Agreement. Notwithstanding the foregoing restrictions on transfer, the Subscriber may, at any time and from time to time during the Restricted Period, transfer the shares (i) as bona fide gifts or transfers by will or intestacy, (ii) to any trust for the direct or indirect benefit of the undersigned or the immediate family of the Subscriber, provided that any such transfer shall not involve a disposition for value, (iii) to a partnership which is the general partner of a partnership of which the Subscriber is a general partner, provided, that, in the case of any gift or transfer described in clauses (i), (ii) or (iii), each donee or transferee agrees in writing to be bound by the terms and conditions contained herein in the same manner as such terms and conditions apply to the undersigned. For purposes hereof, “immediate family” means any relationship by blood, marriage or adoption, not more remote than first cousin.

 

(b)       Beginning on the first day after Lock-up Period, the restrictions on sale of the Lockup Shares set forth herein shall terminate with respect to twenty (20) percent of the Lockup Shares, and on each month thereafter the restrictions with respect to an additional ten (10) percent of the original amount of the Lockup Shares will terminate; such that after nine (9) months (together with the Lockup Period, the “Restriction Period”) all Lockup Shares will be free of the restrictions herein.

 

  5  

 

 

(c)       During the Restricted Period, the Subscriber shall retain all rights of ownership in the Lock-up Shares, including, without limitation, voting rights and the right to receive any dividends that may be declared in respect thereof.

 

(d)       The Company is hereby authorized and required to disclose the existence of this Agreement to its transfer agent. The Company and its transfer agent are hereby authorized and required to decline to make any transfer of the common stock if such transfer would constitute a violation or breach of this Agreement and/or the Purchase Agreement.

 

11.           Miscellaneous .

 

a.             This Warrant shall be binding on and inure to the benefit of the parties hereto and their respective successors and permitted assigns. This Warrant may be amended only in writing and signed by the Company and the Warrant Holder.

 

b.             Nothing in this Warrant shall be construed to give to any person or corporation other than the Company and the Warrant Holder any legal or equitable right, remedy or cause of action under this Warrant; this Warrant shall be for the sole and exclusive benefit of the Company and the Warrant Holder.

 

c.             This Warrant shall be governed by, construed and enforced in accordance with the internal laws of the State of California without regard to the principles of conflicts of law thereof.

 

d.             The headings herein are for convenience only, do not constitute a part of this Warrant and shall not be deemed to limit or affect any of the provisions hereof.

 

e.             In case any one or more of the provisions of this Warrant shall be invalid or unenforceable in any respect, the validity and enforceablilty of the remaining terms and provisions of this Warrant shall not in any way be affected or impaired thereby and the parties will attempt in good faith to agree upon a valid and enforceable provision which shall be a commercially reasonably substitute therefore, and upon so agreeing, shall incorporate such substitute provision in this Warrant.

 

f.             The Warrant Holder shall not, by virtue hereof, be entitled to any voting or other rights of a shareholder of the Company, either at law or equity, and the rights of the Warrant Holder are limited to those expressed in this Warrant.

 

[-signature page follows-]

 

  6  

 

 

IN WITNESS WHEREOF, the Company has caused this Warrant to be duly executed by the authorized officer as of the date first above stated.

 

  LEGACY VENTURES INTERNATIONAL, INC.
   
  By:  
  Name: Randall Letcavage
  Title: Chief Executive Officer

 

  7  

 

 

FORM OF ELECTION TO PURCHASE

 

(To be executed by the Warrant Holder to exercise the right to purchase shares of Common Stock under the foregoing Warrant)

 

To: LEGACY VENTURES INTERNATIONAL, INC.

 

The undersigned, pursuant to the provisions set forth in the attached Warrant (No.____), hereby irrevocably elects to purchase ___ ________ shares of the Common Stock covered by such Warrant.

 

The undersigned herewith makes payment of the full purchase price for such shares at the price per share provided for in such Warrant, which is $___________.

 

The undersigned requests that the certificates for such shares be issued in the name of, and delivered to __________________________________________________________________________________, whose address is ____________________________________________________________________________________________.

 

[signature page follows]

 

The undersigned represents and warrants that all offers and sales by the undersigned of the securities issuable upon exercise of the within Warrant shall be made pursuant to registration of the Common Stock under the Securities Act of 1933, as amended (the “Securities Act”), or pursuant to an exemption from registration under the Securities Act.

 

  Name of Warrant Holder:
   
  (Print)
   
  (By:)
   
  (Name:)
   
  (Title:)
   
  Signatures must conform in all respects to the name of the Warrant Holder on the face of the Warrant.

 

 

8